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Inclusion of albumin as a target in therapy guidelines: Guide-
lines for chronic kidney disease. Slowing the rate of progression
of chronic kidney disease (CKD) as a fundamental manage-
ment goal has been greatly assisted by the development of clin-
ical practice guidelines under the aegis of the National Kidney
Foundation, through the K/DOQI process. Reductions in uri-
nary protein and albumin excretion play important roles in these
treatment strategies, with numerous studies describing short-
and long-term successes in these endeavors. These approaches
may also reduce the risks of cardiovascular and cerebrovascular
morbidity and mortality, and of developing new onset diabetes
mellitus. With enhanced sensitivity assays for urinary albumin,
and the near-term availability of point-of-service testing, we will
have the opportunity to address reduction of urinary albumin
excretion as a defined goal and critical element in management
of CKD. Carefully conducted clinical trials are needed to estab-
lish the utility of these assays, and to define optimal strategies
for reducing urinary albumin excretion. With the successful out-
comes of these studies, the reduction of urinary albumin excre-
tion will receive its due emphasis in the management of patients
with CKD.
Chronic kidney disease (CKD) has been defined in
the National Kidney Foundation Kidney Disease Out-
comes Quality Initiative for CKD [1] as: kidney dam-
age or glomerular filtration rate <60 mL/min/1.73m2 for
three months or longer, where kidney damage is defined
as pathologic abnormalities or markers of damage, in-
cluding abnormalities in blood or urine tests or imaging
studies.
The stages of CKD have been defined with respect to
the level of glomerular filtration rate, with clinical treat-
ment guidelines having been developed that are specific
for each stage. In addition to developing an action plan for
initiation of kidney replacement therapy for patients with
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advanced CKD (i.e., stages 4 and 5 with glomerular filtra-
tion rate <30 mL/min/1.73m2), an important aspect of the
CKD K/DOQI guidelines is the application of treatment
approaches that are intended to slow the functional de-
terioration of CKD, with the specific goal of preventing
the progression to more advance stages of CKD in the
individual patient [1].
Beginning with the angiotensin-converting enzyme
(ACE) inhibitor trials in type 1 diabetes [2], and other
forms of proteinuric kidney diseases [3], and more re-
cently, with the success of the angiotensin AT1 receptor
(ARB) trials in type 2 diabetes [4, 5], the current approach
has focused on the slowing of progression of CKD, with
a special emphasis on concomitant reduction in urinary
protein and albumin excretion. As a treatment goal, the
sustained reduction in urine protein excretion becomes
a part of a comprehensive, maximal approach to treating
proteinuric forms of CKD.
DISCUSSION
The importance of antiproteinuric therapy on the pro-
gression of CKD is a central feature of the comprehen-
sive, maximal approach to slowing progression of CKD,
especially in patients with diabetes mellitus [6, 7]. Re-
cent analysis of the RENAAL data set supports the idea
that reduction in urinary protein excretion is directly re-
lated to the protective effect of these therapies on kid-
ney function. Not only is the reduction of urinary protein
excretion a favorable sign, but also the degree of reduc-
tion is related to the achieved protection against progres-
sion of CKD, as well as cardiovascular risk in the study
population [8].
The annual data report of the United States Renal
Data System (USRDS) also supports the effectiveness of
the current approaches to slowing progression of CKD
(Fig. 1). Diabetes mellitus is the leading cause of end-
stage renal disease (ESRD) in the United States, and its
prevalence as well as the overall prevalence of ESRD
have been the source of major concern, especially related
to projections of the predicted prevalence of ESRD over
the next 10 years [9]. As shown in Figure 1, there now
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Fig. 1. Percentage change in the annual point prevalence of end-stage
renal disease (open columns), and diabetes mellitus (closed columns)
in the United States. Data obtained from the annual data report of the
USRDS (Table B1, 2003, USRDS [9]).
appears to be a favorable trend in the percentage in-
creases in the prevalence of ESRD and ESRD attributed
to diabetes mellitus. Also of note is the apparent mod-
eration of the contribution of diabetes mellitus to the
prevalence of ESRD, with diabetes now contributing in
proportion to its prevalence in the overall ESRD pop-
ulation. One interpretation of this trend, if it holds up
over subsequent years, is that the current approach to
antiproteinuric therapy is indeed slowing the progres-
sion of CKD. Other studies [10–12] have also suggested
that these therapies may reduce the actual incidence of
new-onset diabetes mellitus in adults, which would also
eventually have a favorable impact on the prevalence of
diabetes in the ESRD population.
If the current approach to antiproteinuric therapy of
CKD is having a demonstrable impact on progression
of CKD, what can be done to optimize this approach to
the comprehensive, maximal management of CKD [6, 7]?
The importance of proteinuria and albuminuria as impor-
tant risk factors for the progression of CKD was empha-
sized in a joint consensus conference sponsored by the
NIDDK and the NKF, which was published as on offi-
cial Position Paper of the NKF in 2003 [13]. In addition
to serving as important markers of underlying glomeru-
lar and tubular injury, proteinuria and albuminuria may
themselves contribute, or at least serve as markers for, the
underlying pathophysiologic processes that contribute to
the progression of CKD. In addition to confirming the
current definitions of microalbuminuria (30 to 300 mg
albumin/g creatinine) and macroalbuminuria (>300 mg
albumin/g creatinine), the position paper stated a prefer-
ence for albumin measurement over that for total protein,
and for quantification of urinary albumin excretion rel-
ative to concomitantly measured urinary creatinine. The
position paper noted that the current methods of urinary
albumin radioimmunoassay usually have adequate sensi-
tivity, but that there is a need for standardization among
laboratories for precision and accuracy, especially in the
low-normal range of albumin excretion, with a desired
goal of intra-assay coefficient of variation of <15%.
The mechanisms underlying albuminuria, and the con-
tributions of urinary protein excretion to the processes
underlying the progression of CKD, are the subjects of
renewed recent interest. While changes in glomerular
permeability are important, with microalbuminuria and
especially nephrotic range proteinuria, the tubular pro-
cessing of urinary albumin may also be important in the
progression of CKD. Loss of podocytes removes an im-
portant permeability barrier that then contributes to de-
livery of plasma proteins to the urinary space. In addition,
subsequent fusion of the glomerular capillary basement
membrane to Bowman’s capsule could provide a direct
pathway by which plasma proteins could be directly de-
livered and contribute to inflammatory, proliferative, and
fibrotic reactions in the tubular interstitium [14, 15].
Reactive oxygen species are now felt to participate in
several different pathologic injury models that could con-
tribute to progression of CKD. The direct relation be-
tween angiotensin II and reactive oxygen species has been
emphasized [16–18]. In this context, a number of post-
translational modifications of urinary albumin, such as
lipidation or carbonylation, may serve as important, mea-
surable markers for the underlying inflammatory pro-
cesses at the tubular level [16–18], and quantification
of urinary albumin excretion and its characterization by
preparative approaches [19] may have important utility
in understanding the underlying inflammatory processes
and the responses to specific therapeutic interventions.
CONCLUSION
It appears that albumin excretion is an important vari-
able in the progression of CKD. Not only does the mag-
nitude of albumin and protein excretion relate to the risk
of progression of kidney disease, but post-glomerular al-
bumin processing at the level of the kidney epithelial
cells and interstitium may have important participatory
roles in the processes that contribute to the progression
of CKD. More information is needed about the factors
that affect albumin excretion, both at the level of the
glomerular filtration barrier, as well as the post-filtration
reabsorptive processes. In this context, the mechanisms
of action of recognized “anti-proteinuric” therapies need
to be better defined. With better understanding of these
processes, it may be possible to further refine the in-
tervention strategies in CKD with reduction of urinary
albumin and protein excretion as important end points
beyond the usual hemodynamic targets that are currently
employed. Quantification of urinary excretion of intact
albumin may be an important approach, especially if this
can be made available at the point of care, and if post-
translational modifications of albumin, such as carbony-
lation and lipidation, can be developed that will provide
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novel insights into the inflammatory mechanisms that af-
fect the progression of CKD.
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